Navigation Links
ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis C Patients
Date:8/11/2009

ief Medical Officer added, "We are very encouraged by this data and the potential to further improve response by combining ANA773 with other agents, including ribavirin, an agent that improves response to interferon. Additionally, alternative dosing schedules may further improve pharmacological response to TLR7 activation, as was seen in preclinical studies of ANA773."

In an earlier cohort in which six patients received 1600 mg ANA773 every other day over 28 days, the mean (+/-SEM) maximal decline was 1.0 (+/-0.3) log10 (p>0.1 compared to placebo), with two patients experiencing a maximal decline of greater than 1 log during treatment. The mean end-of-treatment decline was 0.5 log10 at 1600 mg. Patients who received lower doses than 1600 mg showed correspondingly less antiviral response. The Company intends to present complete results from this study at the upcoming Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Oct. 30 - Nov. 3 in Boston.

ANA773 Phase I Clinical Trial in HCV

The Phase I clinical trial of ANA773 in HCV was conducted in the Netherlands under a two-part protocol. Part A of the study included both single and multiple doses of ANA773 in healthy volunteers. Successive cohorts of volunteers received ascending dose levels of ANA773. The primary objectives of Part A of the study were to assess safety and tolerability. Full results from Part A of the study were presented at the EASL Conference in April of this year. In Part B of the study, HCV patients received ANA773 every other day for either 28 or 10 days. The primary objectives of Part B were to assess safety, tolerability and viral load decline. Doses initially explored in Part B of the study were 800 mg, 1200 mg, and 1600 mg dosed every other day for a period of 28 days. Based on the viral load data from the 1600 mg cohort, in April of this year Anadys amended the protocol to include a fourth coho
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Fruitfly Model of a Neuropathic Disease Demonstrates Novel Role for Proteins in the Family of aTyr Pharmas Product Class
2. Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases
3. Thiarabine Demonstrates a Reduction of Both Inflammatory and Erosive Disease Parameters in Rheumatoid Arthritis
4. Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia
5. Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)
6. Study Demonstrates Efficacy of Pitavastatin in Elderly Patients
7. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
8. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
9. Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
10. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
11. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015 Research and Markets ... "Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends ... Video communication has been the topic of fascination ... the United States and the Soviet Russia. Earlier ...
(Date:1/23/2015)... 23, 2015  The Partnership to Fight Chronic Disease (PFCD) released a ... leaders and a new study analyzing the impact of increased cost ... nationwide coalition working to educate policy makers and the public on ... was focused on how the Iowa healthcare ...
(Date:1/23/2015)... 23, 2015  MedScope ( www.medscope.org ), the leading provider ... 2015 Connected World magazine Connected World Award ... that can be used anywhere, anytime. The nomination was ... In nominating MedScope, Landon Garner , Director ...
Breaking Medicine Technology:Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3MedScope Nominated by RacoWireless for Prestigious 2015 Connected World Magazine Connected World Award 2
... Sangart, Inc., a privately held biopharmaceutical company focused ... today announced three new appointments to its executive team. ... the industry,s most influential leaders, while adding to the ... "Sangart believes the quality of our executives should ...
... 15, 2012 /PRNewswire-Asia/ -- China Sky One Medical, Inc. ... CSKI ), a fully integrated pharmaceutical company in ... Mr. Yanqing Liu, the Company,s Chairman, President and Chief ... Following surgery, he is expected to undergo long-term chemotherapy ...
Cached Medicine Technology:Sangart Enhances Leadership Team Bringing Superior Depth of Expertise 2China Sky One Medical Reiterates CEO Sick Leave and Announces Significant Middle Management Resignations 2
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue Cross) wants ... “Live Fearless.” , The “Faces of Fearless” campaign ... how they or someone they know has faced a challenge, ... moment. By telling these types of stories through livefearlessmn.com, participants ...
(Date:1/22/2015)... 22, 2015 Thousand of GranuFlo lawsuits ... recalled its GranuFlo and NaturaLyte dialysis concentrates continue to ... U.S. District Court, District of Massachusetts, Bernstein Liebhard LLP ... Court has remanded a case filed by the state ...
(Date:1/22/2015)... NY (PRWEB) January 22, 2015 ... of Sports Medicine flagship journal Medicine & Science ... L-Citrulline before exercise may help reduce gastrointestinal (GI) ... 1 , Participants in the double-blind, placebo-controlled ...
(Date:1/22/2015)... 2015 Payday lending practices in four ... cause financial distress to the states that permit them, ... University’s Center on Race and Wealth. , While they ... payday loans at the same time substantially depress economic ...
(Date:1/22/2015)... Lower-Auto-Insurance.com has released a new blog post explaining the ... reducing the costs of an auto insurance policy . ... get lower prices for their vehicle insurance policies. The safety a ... policy costs. Because of this, drivers should always carry a ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... 2009 NEW HAVEN, Conn., May 11 VION PHARMACEUTICALS, ... the first quarter of 2009. , , ... per share, for the quarter ended March 31, 2009, compared with ... the same 2008 period. Weighted-average common shares outstanding for the ...
... on the HRS 2009 programST. LOUIS, May 11 ... that the Heart Rhythm 2009 formal program contains 21 ... is either featured or discussed regarding the treatment of ... on the use of Stereotaxis, partnered magnetic irrigated catheter ...
... Mothers Against Drunk Driving (MADD) New York delivered ... showing support for MADD,s Campaign to Eliminate to ... )A key part of MADD,s Campaign to ... the New York State legislature that would expand ...
... Study suggests MRI scans better than questionnaires for evaluations ... seniors who,ve had a stroke fail to report that ... scans rather than patient self-reporting to determine stroke history. ... years and older (average age 80.1) in Manhattan. They ...
... 2009 Iron chelating drugs have been heavily promoted ... form of blood cancer often treated with blood transfusion. ... body, are highly expensive and potentially toxic. A new ... finds that their increased use has been propagated by ...
... neutral, global, multidisciplinary association of professionals involved in the lifecycle ... Career Center--a highly targeted resource for online employment connections. ... ... 11, 2009 -- The Drug Information Association (DIA) , ...
Cached Medicine News:Health News:Vion Pharmaceuticals Reports 2009 First Quarter Results 2Health News:Vion Pharmaceuticals Reports 2009 First Quarter Results 3Health News:Vion Pharmaceuticals Reports 2009 First Quarter Results 4Health News:Vion Pharmaceuticals Reports 2009 First Quarter Results 5Health News:Stereotaxis' Market Leadership Highlighted at Heart Rhythm 2009 2Health News:Stereotaxis' Market Leadership Highlighted at Heart Rhythm 2009 3Health News:Stereotaxis' Market Leadership Highlighted at Heart Rhythm 2009 4Health News:MADD Delivers Nearly 7,000 Petitions to Governor Paterson Urging Ignition Interlocks For All Convicted DWI Offenders 2Health News:Seniors Often Misstate Stroke History 2Health News:Drug Information Association (DIA) Launches New Online Career Center 2Health News:Drug Information Association (DIA) Launches New Online Career Center 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: